Zacks: Brokerages Anticipate Humana Inc (HUM) Will Post Earnings of $4.29 Per Share

Share on StockTwits

Equities research analysts predict that Humana Inc (NYSE:HUM) will report earnings per share (EPS) of $4.29 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Humana’s earnings, with the lowest EPS estimate coming in at $3.92 and the highest estimate coming in at $4.42. Humana posted earnings per share of $3.39 during the same quarter last year, which suggests a positive year-over-year growth rate of 26.5%. The business is scheduled to announce its next earnings report before the market opens on Wednesday, November 7th.

According to Zacks, analysts expect that Humana will report full year earnings of $14.18 per share for the current fiscal year, with EPS estimates ranging from $14.14 to $14.25. For the next year, analysts expect that the business will report earnings of $17.33 per share, with EPS estimates ranging from $16.92 to $18.09. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Humana.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, topping the Zacks’ consensus estimate of $3.79 by $0.17. The business had revenue of $14.26 billion for the quarter, compared to the consensus estimate of $14.16 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same period in the prior year, the firm earned $3.49 EPS.

A number of equities analysts have commented on HUM shares. Piper Jaffray Companies restated a “buy” rating and issued a $355.00 target price on shares of Humana in a research note on Thursday, August 2nd. Bank of America upped their target price on shares of Humana from $338.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Jefferies Financial Group upped their target price on shares of Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Wednesday, July 4th. Finally, Argus upped their target price on shares of Humana to $375.00 and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $339.79.

In related news, insider Roy A. Beveridge sold 14,306 shares of the stock in a transaction that occurred on Monday, August 6th. The shares were sold at an average price of $324.25, for a total transaction of $4,638,720.50. Following the completion of the sale, the insider now owns 15,274 shares of the company’s stock, valued at $4,952,594.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Cynthia H. Zipperle sold 4,886 shares of the stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $321.89, for a total transaction of $1,572,754.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,284 shares of company stock worth $13,147,715. Insiders own 0.60% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Alps Advisors Inc. lifted its position in Humana by 10.0% during the second quarter. Alps Advisors Inc. now owns 3,675 shares of the insurance provider’s stock valued at $1,094,000 after acquiring an additional 334 shares during the last quarter. Sio Capital Management LLC purchased a new stake in Humana during the second quarter valued at approximately $5,296,000. Columbus Hill Capital Management L.P. lifted its position in Humana by 57.6% during the second quarter. Columbus Hill Capital Management L.P. now owns 150,759 shares of the insurance provider’s stock valued at $44,870,000 after acquiring an additional 55,100 shares during the last quarter. Synovus Financial Corp lifted its position in Humana by 231.6% during the second quarter. Synovus Financial Corp now owns 1,227 shares of the insurance provider’s stock valued at $365,000 after acquiring an additional 857 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Humana by 1.2% during the second quarter. Northern Trust Corp now owns 1,687,211 shares of the insurance provider’s stock valued at $502,164,000 after acquiring an additional 20,480 shares during the last quarter. 92.84% of the stock is owned by institutional investors.

HUM stock traded down $3.93 during mid-day trading on Monday, reaching $328.38. The company had a trading volume of 646,629 shares, compared to its average volume of 559,522. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43. The company has a market capitalization of $45.78 billion, a P/E ratio of 28.04, a P/E/G ratio of 1.66 and a beta of 0.97. Humana has a 12 month low of $231.90 and a 12 month high of $341.30.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 26th. Stockholders of record on Friday, September 28th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.61%. Humana’s dividend payout ratio is presently 17.08%.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: Understanding Analyst Ratings

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply